Effect of neoadjuvant chemotherapy on R0 resection rate of esophageal carcinoma
- Author:
- No author available
- Journal Title:
- CANCER RESEARCH AND CLINIC
- Issue:
- 5
- DOI:
- 10.3760/cma.j.issn.1006-9801.2010.05.003
- Key Word:
- 食管肿瘤;新辅助化疗;R0切除率;Esophageal neoplasms;Neoadjuvant chemotherapy;R0 resection rate
Abstract： Objective To investigate the possibility of increasing R0 resection rate in esophageal carcinoma after neoadjuvant chemotherapy. Methods 30 patients underwent operation after neoadjuvant chemotherapy mainly by paclitaxel combined with cis-platinum, including 18 squamous carcinoma cases. 10 adenocarcinoma cases and 2 small cell carcinoma cases.Results In these 30 patients,the overall effective rate of neoadjuvant chemotherapy is 56.7%(17/30)(CR+PR),R0 resection rate is 100%,and the incidence rate of anastomotic leakage is 3.3%(1/30),without perioperative death.Conclusion The neoadjuvant chemotherapv is significant in improving the R0 resection rate in esophageal carcinoma,and the impact of long-term survival after surgery needs further follow-up.
- [1]邵令方,高宗人,卫功铨,等.食管癌和贲门癌的外科治疗[J].2001,(1).
- [2]王秀芳,郑玄中,靳宏星.食管癌淋巴结转移影像诊断方法及进展[J].2009,(5).
- [3]P, Schlag,R, Herrmann,U, Raeth,etc.Preoperative (neoadjuvant) chemotherapy in squamous cell cancer of the esophagus.[J].1988,110.
- [4]Willett CG,Minsky BD,Ajani JA,etc.Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer.[J].2007,25(24).
- [5]Ajani J,Roth JA,Minsky BD,etc.Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer (see comments)[J].1998,339(27).
- [6]J A, Ajani,D H, Ilson,K, Daugherty,etc.Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus.[J].1994,86.
- [7]Van Der Gaast A,Eskens FA,Polee MB,etc.Phase II study of neo-adjuvant chemotherapy with paclitaxel and cisplatin given every 2 weeks for patients with a resectable squamous cell carcinoma of the esophagus.[J].2003,14(8).
- [8]Merrill S. Kies,Steven T. Rosen,Tat-Kin Tsang,etc.Cisplatin and 5-fluorouracil in the primary management of squamous esophageal cancer[J].1987,60(9).
- [9]Wanders J,Kaplan RS,Eisenhauer EA,etc.New guidelines to evaluate the response to treatment in solid tumors (see comments)[J].2000,92(3).
- [10]Boso C,Peracchia A,Sileni VC,etc.Trends in management and prognosis for esophageal cancer surgery: twenty-five years of experience at a single institution.[J].2009,144(3).
- [11]N, Gunduz,B, Fisher,E A, Saffer.Effect of surgical removal on the growth and kinetics of residual tumor.[J].1979,39.
- [12]Foo K,Simes J,Smithers BM,etc.Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.[J].2007,8(3).
- [13]Allum WH,Stenning SP,Bancewicz J.Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.[J].2009,27(30).
- [14]Smith IE,Prendiville J,Ramage F,etc.High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer.[J].1995,13(2).
- [15]B, Fisher,E, Saffer,C, Rudock,etc.Effect of local or systemic treatment prior to primary tumor removal on the production and response to a serum growth-stimulating factor in mice.[J].1989,49.
- [16]A D, Hilgenberg,R W, Carey,E W, Wilkins,etc.Preoperative chemotherapy, surgical resection, and selective postoperative therapy for squamous cell carcinoma of the esophagus.[J].1988,45(4).